Trial Profile
A Phase III, Multicentre, Randomised, Double-Blind, Comparative Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Feb 2019
Price :
$35
*
At a glance
- Drugs Ceftaroline fosamil (Primary) ; Ceftriaxone
- Indications Community-acquired pneumonia
- Focus Registrational; Therapeutic Use
- Sponsors AstraZeneca
- 28 Dec 2018 Results assessing safety and tolerability of ceftaroline fosamil q8h and q12h regimens using data from 6 phase three trials (NCT01499277, NCT00424190, NCT00423657, NCT01371838, NCT00621504 and NCT00509106) published in the Journal of Antimicrobial Chemotherapy
- 24 Apr 2018 Results assessing comparison of safety profile of two regimens of ceftaroline fosamil by using data from six phase III studies (COVERS, CANVAS 1, CANVAS 2, FOCUS 1, FOCUS 2, and asian CAP) presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases.
- 12 Apr 2016 Results from CANVAS-1, CANVAS 2, COVERS, FOCUS 1, FOCUS 2 and Asia CAP trials (n=4055) presented at the 26th European Congress of Clinical Microbiology and Infectious Diseases